ARS Pharmaceuticals, Inc.
SPRY
$5.24
-$0.15-2.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 33.66M | 22.68M | 28.09M | 32.50M | 15.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.66M | 22.68M | 28.09M | 32.50M | 15.72M |
| Cost of Revenue | 17.54M | 10.62M | 9.60M | 10.94M | 9.02M |
| Gross Profit | 16.11M | 12.06M | 18.49M | 21.56M | 6.70M |
| SG&A Expenses | 77.58M | 72.20M | 59.96M | 74.75M | 54.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.12M | 82.83M | 69.55M | 85.69M | 63.33M |
| Operating Income | -61.47M | -60.15M | -41.47M | -53.19M | -47.61M |
| Income Before Tax | -62.34M | -60.62M | -41.40M | -51.15M | -44.88M |
| Income Tax Expenses | -- | -- | -80.00K | -- | -- |
| Earnings from Continuing Operations | -62.34M | -60.62M | -41.32M | -51.15M | -44.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.34M | -60.62M | -41.32M | -51.15M | -44.88M |
| EBIT | -61.47M | -60.15M | -41.47M | -53.19M | -47.61M |
| EBITDA | -61.05M | -59.75M | -41.05M | -52.80M | -47.34M |
| EPS Basic | -0.63 | -0.61 | -0.42 | -0.52 | -0.46 |
| Normalized Basic EPS | -0.39 | -0.38 | -0.23 | -0.32 | -0.29 |
| EPS Diluted | -0.63 | -0.61 | -0.42 | -0.52 | -0.46 |
| Normalized Diluted EPS | -0.39 | -0.38 | -0.23 | -0.32 | -0.29 |
| Average Basic Shares Outstanding | 99.31M | 99.30M | 99.03M | 98.81M | 98.36M |
| Average Diluted Shares Outstanding | 99.31M | 99.30M | 99.03M | 98.81M | 98.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |